ANIK vs NVCR

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -5. 9% for Anika Therapeutics, Inc. (ANIK). Analysts rate Anika Therapeutics, Inc. (ANIK) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Anika Therapeutics, Inc.

(ANIK) delivered a total return of -64. 4%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +38. 5% versus ANIK's -66. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Anika Therapeutics, Inc.

(ANIK) is the lower-risk stock at 1. 10β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 95% more volatile than ANIK relative to the S&P 500. On balance sheet safety, Anika Therapeutics, Inc. (ANIK) carries a lower debt/equity ratio of 17% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -5. 9% for Anika Therapeutics, Inc. (ANIK). On earnings-per-share growth, the picture is similar: Anika Therapeutics, Inc. grew EPS 80. 2% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Anika Therapeutics, Inc.

(ANIK) is the more profitable company, earning -9. 6% net margin versus -20. 8% for NovoCure Limited — meaning it keeps -9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANIK leads at -9. 8% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Anika Therapeutics, Inc.

(ANIK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10)). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ANIK: -66. 7%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.